Herpes zoster and vaccination: A clinical review
- Herpes zoster vax cost effective in older adults in Belgium? // PharmacoEconomics & Outcomes News;1/7/2012, Issue 644, p6
The article discusses research study on the cost-effectiveness of the varicella zoster virus vaccine Zostavax against herpes zoster in adults aged over 60 years in Belgium. It references a study by J. Bilcke et al published in the November 24, 2011 issue of "Vaccine." The researchers have...
- Vaccine Approved for Shingles in Older People. // FDA Consumer;Sep/Oct2006, Vol. 40 Issue 5, p38
The article offers information on Zostavax, a vaccine that could reduce the risk of shingles in older people. Shingles is a disease caused by the varicella-zoster virus, the same virus that causes chickenpox. The vaccine not only prevented approximately half of the cases, but also slightly...
- Herpes Zoster Vaccination Indication Extended to Younger Individuals. Deresinski, Stan // Infectious Disease Alert;Jun2011, Vol. 30 Issue 9, p101
The article discusses the results of a new trial on the use of Zostavax herpes zoster (HZ) vaccine in people between the ages 50 to 59.
- WEST NILE A Vaccine on the Way ... But Not This Summer. Carmichael, Mary // Newsweek;6/7/2004, Vol. 143 Issue 23, p14
Offers a look at the development of a vaccine for the West Nile virus. Discussion of the long-term effects of the disease including shortness of breath, fevers, pain, paralysis and irreversible nerve damage; Report on a clinical trial of a vaccine by Acambis.
- Evaluation of the Immune Response to a 2-Dose Measles Vaccination Schedule Administered at 6 and 9 Months of Age to HIV-Infected and HIV-Uninfected Children in Malawi. Helfand, Rita F.; Witte, Desiree; Fowlkes, Ashley; Garcia, Philip; Chunfu Yang; Fudzulani, Richard; Walls, Laura; Sun Bae; Strebel, Peter; Broadhead, Robin; Bellini, William J.; Cutts, Felicity // Journal of Infectious Diseases;11/15/2008, Vol. 198 Issue 10, p1457
Background. The World Health Organization recommends that infants at high risk for developing measles before 9 months of age, including human immunodeficiency virus (HIV)--infected infants, receive measles vaccination (MV) at 6 and 9 months of age. Methods. Children born to HIV-infected mothers...
- Herpes zoster vaccination "might" be worth it in the Netherlands. // PharmacoEconomics & Outcomes News;1/26/2013, Issue 670, p8
The article discusses research which examined the cost-effectiveness of herpes zoster vaccination in the Netherlands, referencing a study by P. T. de Boer and colleagues, published in the January 7, 2013 issue of "Vaccine."
- Breaking down the cost-benefit equation. // Hospital Employee Health;Apr2009, Vol. 28 Issue 4, p40
The article discusses the cost effectiveness of pertussis vaccines for health care workers, quantiFERON-TB Gold for tuberculosis screening, and powered air-purifying respirators for exposure to airborne infections. It describes the guidelines and financial implications for each. An example of...
- Eradication versus control: the economics of global infectious disease policies. Barrett, Scott // Bulletin of the World Health Organization;Sep2004, Vol. 82 Issue 9, p683
A disease is controlled if, by means of a public policy, the circulation of an infectious agent is restricted below the level that would be sustained by individuals acting independently to control the disease. A disease is eliminated if it is controlled sufficiently to prevent an epidemic from...
- Correction: Geographical Variability in the Likelihood of Bloodstream Infections Due to Gram-Negative Bacteria: Correlation with Proximity to the Equator and Health Care Expenditure. null, null // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1
No abstract available.